Khanh Ngoc Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khanh Ngoc Nguyen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Chi Dung Vu
Center of Endocrinology, Metabolism, Genetic/Genomics and Molecular Therapy, Vietnam National Children’s Hospital, 18/879 La Thanh, Dong Da, Hanoi 11512, Vietnam
5 shared publications - Thi Bich Ngoc Can
Center of Endocrinology, Metabolism, Genetic/Genomics and Molecular Therapy, Vietnam National Children’s Hospital, 18/879 La Thanh, Dong Da, Hanoi 11512, Vietnam
5 shared publications - Ha Thu Nguyen
National Children's Hospital Hanoi Vietnam
2 shared publications - Pham Quang Duy
University of Britist Columbia Vancouver British Columbia Canada
2 shared publications - Thao Bui Phuong
The Center for Endocrinology, Metabolism, Genetics/Genomic and Molecular Therapy, National Children
2 shared publications - Tran Minh Dien
The Center of Endocrinology, Metabolism, Genetics and Molecular Therapy, Vietnam National Children's Hospital, Hanoi, Viet Nam
2 shared publications
Latest Publications
- 13 November 2026
- Published by Wiley in Clinical Endocrinology
Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6–8 With Central Precocious Puberty
Background: Brain magnetic resonance imaging (MRI) is recommended for selected girls with central precocious puberty (CPP). Routine brain magnetic resonance imaging (MRI) in girls aged 6–8 years with central precocious puberty (CPP) remains clinically controversial. Neurological features may help identify girls at higher risk, but whether basal luteinizing hormone (LH), a routinely measured marker of hypothalamic–pituitary–gonadal axis activation, provides additional information beyond age at diagnosis remains uncertain. Methods: In this retrospective cross‐sectional study, 848 girls aged 6–8 years diagnosed with CPP underwent brain MRI at Vietnam National Children's Hospital between April 2021 and June 2026. Brain MRI findings were classified as clinically significant/pathological, uncertain/questionable significance, or incidental. Neurological characteristics were compared across the MRI categories. Logistic regression was used to identify factors associated with clinically significant MRI abnormalities. Sequential models evaluated whether basal LH provided additional information beyond age at diagnosis, with model fit and discrimination assessed using likelihood‐ratio tests, Akaike information criterion (AIC) and area under the receiver operating characteristic curve (AUC). Results: Any brain MRI abnormalities were identified in 86 girls (10.1%), including 30 (3.5%) with clinically significant central nervous system (CNS) lesions, 14 (1.7%) with questionable findings and 42 (5.0%) with incidental findings. Neurological symptoms, signs or previous CNS history were more frequent among girls with clinically significant abnormalities than among those with uncertain or incidental findings (30.0%, 7.1% and 4.8%, respectively; p = 0.012). Basal LH was independently associated with clinically significant MRI abnormalities (adjusted OR 1.30 per IU/L, 95% CI 1.14–1.47; p < 0.001. Adding basal LH to age at diagnosis significantly improved model fit (AIC 247.79 vs. 259.78; likelihood‐ratio p = 0.0002), although discrimination remained modest (AUC 0.654 vs. 0.550 for age alone, p = 0.055). Bone‐age advancement did not provide significant additional information. Conclusions: In girls aged 6–8 years with CPP, brain MRI abnormalities were identified in approximately 1 in 10 girls, but most were incidental or of uncertain clinical significance. Clinically significant abnormalities were enriched among girls with neurological features. Basal LH provided incremental information beyond age at diagnosis but had limited discriminatory performance. These findings support a risk‐stratified approach to brain MRI in girls aged 6–8 years with CPP, with careful neurological assessment remaining central to imaging decisions.
- 13 November 2026
- Published by Wiley in Clinical Endocrinology
Brain MRI Findings and Factor Associated With Clinical Significant CNS Lesions in Girls Aged 6–8 With Central Precocious Puberty
Background: Brain magnetic resonance imaging (MRI) is recommended for selected girls with central precocious puberty (CPP). Routine brain magnetic resonance imaging (MRI) in girls aged 6–8 years with central precocious puberty (CPP) remains clinically controversial. Neurological features may help identify girls at higher risk, but whether basal luteinizing hormone (LH), a routinely measured marker of hypothalamic–pituitary–gonadal axis activation, provides additional information beyond age at diagnosis remains uncertain. Methods: In this retrospective cross‐sectional study, 848 girls aged 6–8 years diagnosed with CPP underwent brain MRI at Vietnam National Children's Hospital between April 2021 and June 2026. Brain MRI findings were classified as clinically significant/pathological, uncertain/questionable significance, or incidental. Neurological characteristics were compared across the MRI categories. Logistic regression was used to identify factors associated with clinically significant MRI abnormalities. Sequential models evaluated whether basal LH provided additional information beyond age at diagnosis, with model fit and discrimination assessed using likelihood‐ratio tests, Akaike information criterion (AIC) and area under the receiver operating characteristic curve (AUC). Results: Any brain MRI abnormalities were identified in 86 girls (10.1%), including 30 (3.5%) with clinically significant central nervous system (CNS) lesions, 14 (1.7%) with questionable findings and 42 (5.0%) with incidental findings. Neurological symptoms, signs or previous CNS history were more frequent among girls with clinically significant abnormalities than among those with uncertain or incidental findings (30.0%, 7.1% and 4.8%, respectively; p = 0.012). Basal LH was independently associated with clinically significant MRI abnormalities (adjusted OR 1.30 per IU/L, 95% CI 1.14–1.47; p < 0.001. Adding basal LH to age at diagnosis significantly improved model fit (AIC 247.79 vs. 259.78; likelihood‐ratio p = 0.0002), although discrimination remained modest (AUC 0.654 vs. 0.550 for age alone, p = 0.055). Bone‐age advancement did not provide significant additional information. Conclusions: In girls aged 6–8 years with CPP, brain MRI abnormalities were identified in approximately 1 in 10 girls, but most were incidental or of uncertain clinical significance. Clinically significant abnormalities were enriched among girls with neurological features. Basal LH provided incremental information beyond age at diagnosis but had limited discriminatory performance. These findings support a risk‐stratified approach to brain MRI in girls aged 6–8 years with CPP, with careful neurological assessment remaining central to imaging decisions.
- 1 October 2026
- Published by Wiley in Clinical Endocrinology
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency
Objective: Growth hormone deficiency (GHD) is an important cause of growth failure in children. Although recombinant human growth hormone (rhGH) promotes catch‐up growth, longitudinal differences in treatment response between isolated growth hormone deficiency (IGHD) and combined pituitary hormone deficiency (CPHD) remain unclear. This study compared longitudinal growth trajectories during rhGH therapy between IGHD and CPHD patients. Design and Patients: A retrospective cohort study included 72 IGHD and 48 CPHD patients. Measurements: Height standard deviation score (SDS) was assessed at baseline and after 12, 24, 36 and 48 months of rhGH therapy. Longitudinal trajectories were analysed using linear mixed‐effects models adjusted for age at treatment initiation, bone age, BMI SDS and pituitary MRI findings. Results: CPHD patients had more severe growth impairment at baseline than those with IGHD (height SDS: −5.00 ± 1.57 vs. −3.20 ± 1.12; p < 0.001). However, CPHD demonstrated greater catch‐up growth, achieving larger cumulative height SDS gains after 48 months (3.10 ± 1.36 vs. 1.92 ± 0.87 SDS; p < 0.001). Mixed‐effects modelling confirmed significantly different longitudinal growth trajectories (time‐by‐diagnosis interaction: χ 2 = 66.62, p < 0.001). Adjusted height SDS improved from −3.40 to −1.49 in IGHD and from −4.56 to −1.55 in CPHD. At 48 months, the adjusted CPHD–IGHD difference was −0.06 SDS (95% CI, −0.63 to 0.51), consistent with substantial convergence of the two growth trajectories. Older age at treatment initiation and abnormal pituitary MRI findings were independently associated with lower height SDS across follow‐up. Conclusions: Despite more severe baseline growth impairment, children with CPHD experienced greater catch‐up growth during rhGH therapy, resulting in substantial convergence of longitudinal height SDS trajectories toward those of children with IGHD over 4 years.
- 1 October 2026
- Published by Wiley in Clinical Endocrinology
Converging Growth Trajectories During Recombinant Human Growth Hormone Therapy in Children With Isolated and Combined Pituitary Hormone Deficiency
Objective: Growth hormone deficiency (GHD) is an important cause of growth failure in children. Although recombinant human growth hormone (rhGH) promotes catch‐up growth, longitudinal differences in treatment response between isolated growth hormone deficiency (IGHD) and combined pituitary hormone deficiency (CPHD) remain unclear. This study compared longitudinal growth trajectories during rhGH therapy between IGHD and CPHD patients. Design and Patients: A retrospective cohort study included 72 IGHD and 48 CPHD patients. Measurements: Height standard deviation score (SDS) was assessed at baseline and after 12, 24, 36 and 48 months of rhGH therapy. Longitudinal trajectories were analysed using linear mixed‐effects models adjusted for age at treatment initiation, bone age, BMI SDS and pituitary MRI findings. Results: CPHD patients had more severe growth impairment at baseline than those with IGHD (height SDS: −5.00 ± 1.57 vs. −3.20 ± 1.12; p < 0.001). However, CPHD demonstrated greater catch‐up growth, achieving larger cumulative height SDS gains after 48 months (3.10 ± 1.36 vs. 1.92 ± 0.87 SDS; p < 0.001). Mixed‐effects modelling confirmed significantly different longitudinal growth trajectories (time‐by‐diagnosis interaction: χ 2 = 66.62, p < 0.001). Adjusted height SDS improved from −3.40 to −1.49 in IGHD and from −4.56 to −1.55 in CPHD. At 48 months, the adjusted CPHD–IGHD difference was −0.06 SDS (95% CI, −0.63 to 0.51), consistent with substantial convergence of the two growth trajectories. Older age at treatment initiation and abnormal pituitary MRI findings were independently associated with lower height SDS across follow‐up. Conclusions: Despite more severe baseline growth impairment, children with CPHD experienced greater catch‐up growth during rhGH therapy, resulting in substantial convergence of longitudinal height SDS trajectories toward those of children with IGHD over 4 years.
- Open Access
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
GENOTYPE–PHENOTYPE SPECTRUM AND CLINICAL OUTCOMES OF GLYCOGEN STORAGE DISEASE TYPE I: A 15-YEAR EXPERIENCE AT VIETNAM NATIONAL CHILDREN’S HOSPITAL
Background: Glycogen Storage Disease Type I (GSD I) is an inherited metabolic disorder characterized by impaired hepatic glucose production due to defects in gluconeogenesis and glycogenolysis. Two subtypes are recognized: GSD Ia (G6PC) and GSD Ib (SLC37A4). Genotype–phenotype correlations and long-term outcomes in Southeast Asia remain insufficiently characterized. This study aimed to describe the clinical, biochemical, and molecular features of Vietnamese children with GSD I and evaluate treatment outcomes. Methods: Twenty-four patients from 19 families diagnosed at the Vietnam National Children’s Hospital between 2016 and 2025 were included. All underwent genetic testing. Clinical characteristics and laboratory parameters were collected at diagnosis and during follow-up. Results: Twelve distinct variants were identified, including eight in G6PC and four in SLC37A4, with one novel variant (c.1193G>A). The most common G6PC variants were c.518T>C, c.356A>T, and c.648G>T, while c.706_708delGTG predominated in SLC37A4. The median age at symptom onset was 4 months, and 70% of patients presented with hepatomegaly. Elevated liver enzymes and lactate levels were observed in all cases, and 88.2% had hypertriglyceridemia. Dietary adherence was generally poor despite uncooked cornstarch therapy. During follow-up, patients with GSD Ia developed complications including short stature, hepatic adenoma, pancreatitis, hypertension, kidney stones, and cirrhosis, while all GSD Ib patients experienced neutropenia and required empagliflozin for recurrent infections. Conclusion: Hepatomegaly with elevated liver enzymes, lactate, and triglycerides is a common presentation of GSD I. Variant distribution may differ across populations, and complications can occur at any age
- 22 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGENOTYPE–PHENOTYPE SPECTRUM AND CLINICAL OUTCOMES OF GLYCOGEN STORAGE DISEASE TYPE I: A 15-YEAR EXPERIENCE AT VIETNAM NATIONAL CHILDREN’S HOSPITAL
Background: Glycogen Storage Disease Type I (GSD I) is an inherited metabolic disorder characterized by impaired hepatic glucose production due to defects in gluconeogenesis and glycogenolysis. Two subtypes are recognized: GSD Ia (G6PC) and GSD Ib (SLC37A4). Genotype–phenotype correlations and long-term outcomes in Southeast Asia remain insufficiently characterized. This study aimed to describe the clinical, biochemical, and molecular features of Vietnamese children with GSD I and evaluate treatment outcomes. Methods: Twenty-four patients from 19 families diagnosed at the Vietnam National Children’s Hospital between 2016 and 2025 were included. All underwent genetic testing. Clinical characteristics and laboratory parameters were collected at diagnosis and during follow-up. Results: Twelve distinct variants were identified, including eight in G6PC and four in SLC37A4, with one novel variant (c.1193G>A). The most common G6PC variants were c.518T>C, c.356A>T, and c.648G>T, while c.706_708delGTG predominated in SLC37A4. The median age at symptom onset was 4 months, and 70% of patients presented with hepatomegaly. Elevated liver enzymes and lactate levels were observed in all cases, and 88.2% had hypertriglyceridemia. Dietary adherence was generally poor despite uncooked cornstarch therapy. During follow-up, patients with GSD Ia developed complications including short stature, hepatic adenoma, pancreatitis, hypertension, kidney stones, and cirrhosis, while all GSD Ib patients experienced neutropenia and required empagliflozin for recurrent infections. Conclusion: Hepatomegaly with elevated liver enzymes, lactate, and triglycerides is a common presentation of GSD I. Variant distribution may differ across populations, and complications can occur at any age
- Open Access
- 31 December 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (6) , 330-339
Clinical and molecular characteristics of simple virilizing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: insight from a tertiary pediatric center in Vietnam
Purpose: Simple virilizing congenital adrenal hyperplasia (SV-CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disease caused by pathogenic variants of the CYP21A2 gene. Children with SV-CAH often experience delayed diagnosis, presenting with pseudo-precocious puberty in males and genital virilization in females. Genotyping is essential for diagnosis, treatment, optimization, and phenotype prediction. This study describes the clinical and genetic characteristics of SV-CAH to guide treatment strategies.Methods: From November 2016 to March 2023, 79 children (accounting for 34.3% of 230 CAH cases in the overall children’s cohort) from 75 families were classified as SV-CAH due to 21-OHD at the Vietnam National Children's Hospital. Forty-three children underwent CYP21A2 mutation analysis using multiplex ligation-dependent probe amplification and complete gene sequencing to detect pathogenic variants.Results: Median age at diagnosis was 4.5 years (interquartile range, 1 day–22.3 years). There were 38.0% males and 62.0% females. The most common symptoms were penile enlargement in males (53.3%) and clitoromegaly (87.8%) in females; the height standard deviation (SD) at diagnosis was 1.90±1.79 SD (-2.02 to 5.43) according to the World Health Organization; and bone age advancement was 4.65±2.59 years. Genetic analysis identified 21 pathogenic variants and 22 genotypes in 43 children. The most common variant was p.I173N (47.7%); the most common genotype was p.I173N/p.I173N (16.3%).Conclusion: Children with SV-CAH are often diagnosed late. To avoid that, early genetic analysis should be prioritized, especially for children diagnosed through newborn screening programs. Determining the genotype is crucial for optimizing treatment strategies, ensuring personalized management, and avoiding overtreatment.
- 31 December 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (6) , 330-339
Open AccessClinical and molecular characteristics of simple virilizing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: insight from a tertiary pediatric center in Vietnam
Purpose: Simple virilizing congenital adrenal hyperplasia (SV-CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disease caused by pathogenic variants of the CYP21A2 gene. Children with SV-CAH often experience delayed diagnosis, presenting with pseudo-precocious puberty in males and genital virilization in females. Genotyping is essential for diagnosis, treatment, optimization, and phenotype prediction. This study describes the clinical and genetic characteristics of SV-CAH to guide treatment strategies.Methods: From November 2016 to March 2023, 79 children (accounting for 34.3% of 230 CAH cases in the overall children’s cohort) from 75 families were classified as SV-CAH due to 21-OHD at the Vietnam National Children's Hospital. Forty-three children underwent CYP21A2 mutation analysis using multiplex ligation-dependent probe amplification and complete gene sequencing to detect pathogenic variants.Results: Median age at diagnosis was 4.5 years (interquartile range, 1 day–22.3 years). There were 38.0% males and 62.0% females. The most common symptoms were penile enlargement in males (53.3%) and clitoromegaly (87.8%) in females; the height standard deviation (SD) at diagnosis was 1.90±1.79 SD (-2.02 to 5.43) according to the World Health Organization; and bone age advancement was 4.65±2.59 years. Genetic analysis identified 21 pathogenic variants and 22 genotypes in 43 children. The most common variant was p.I173N (47.7%); the most common genotype was p.I173N/p.I173N (16.3%).Conclusion: Children with SV-CAH are often diagnosed late. To avoid that, early genetic analysis should be prioritized, especially for children diagnosed through newborn screening programs. Determining the genotype is crucial for optimizing treatment strategies, ensuring personalized management, and avoiding overtreatment.
- Open Access
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 250-259
Incidence rate and characteristics of newly diagnosed type 1 diabetes in a Vietnamese tertiary pediatric center: challenges in early detection
Purpose: This study aims to estimate the incidence and examine the clinical and laboratory characteristics of newly diagnosed type 1 diabetes (T1D) in Vietnamese children at a tertiary referral pediatric hospital.Methods: A retrospective cross-sectional analysis was conducted on 64 children newly diagnosed with T1D at Vietnam National Children's Hospital in 2023. Data on the children were analyzed, including demographics, family history, symptoms, anthropometric measurements, hemoglobin A1c levels, and pancreatic islet autoantibodies.Results: The average age at diagnosis was 9.1±3.7 years, with a male predominance (53.1%). The incidence rate of T1D in these northern Vietnamese children was 0.77 per 100,000 children. Diabetic ketoacidosis (DKA) was present in 57.8% of children at diagnosis, and 75% tested positive for autoantibodies. The Red River Delta reported the highest proportion of children with T1D (43.5%), but the incidence rate was highest in Hanoi, the capital city (0.91 per 100,000 children).Conclusion: This study underscores the considerable diagnostic delays in T1D in a tertiary pediatric center in Vietnam, with a high prevalence of DKA. The results highlight the need for an enhanced network of satellite hospitals to enable early diagnosis and treatment for patients.
- 31 October 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (5) , 250-259
Open AccessIncidence rate and characteristics of newly diagnosed type 1 diabetes in a Vietnamese tertiary pediatric center: challenges in early detection
Purpose: This study aims to estimate the incidence and examine the clinical and laboratory characteristics of newly diagnosed type 1 diabetes (T1D) in Vietnamese children at a tertiary referral pediatric hospital.Methods: A retrospective cross-sectional analysis was conducted on 64 children newly diagnosed with T1D at Vietnam National Children's Hospital in 2023. Data on the children were analyzed, including demographics, family history, symptoms, anthropometric measurements, hemoglobin A1c levels, and pancreatic islet autoantibodies.Results: The average age at diagnosis was 9.1±3.7 years, with a male predominance (53.1%). The incidence rate of T1D in these northern Vietnamese children was 0.77 per 100,000 children. Diabetic ketoacidosis (DKA) was present in 57.8% of children at diagnosis, and 75% tested positive for autoantibodies. The Red River Delta reported the highest proportion of children with T1D (43.5%), but the incidence rate was highest in Hanoi, the capital city (0.91 per 100,000 children).Conclusion: This study underscores the considerable diagnostic delays in T1D in a tertiary pediatric center in Vietnam, with a high prevalence of DKA. The results highlight the need for an enhanced network of satellite hospitals to enable early diagnosis and treatment for patients.